Disease · MONDO_0043494

arteritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. arteritis. Diseases, record MONDO_0043494. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043494

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: arteritis; Open Targets
Open Targets ID: MONDO_0043494; Open Targets
Other names: artery inflammation, inflammation of artery; Open Targets
MeSH: D001167; MeSH
NCI Thesaurus: C34399; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 1 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CENICRIVIROC MESYLATE	CHEMBL2105686	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VB-201	CHEMBL4297333	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD14	Monocyte differentiation antigen CD14	1	Monocyte differentiation antigen CD14 inhibitor	Phase 1/2	https://conductscience.org/library/genes/929	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Unknown	https://conductscience.org/library/genes/1719	Drugs and targets
TLR2	Toll-like receptor 2	1	Toll-like receptor 2 inhibitor	Phase 1/2	https://conductscience.org/library/genes/7097	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05630885	A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV	Phase 2	110	2025-07-16	HIV-1-infection, Elevated Cardiovascular Risk	CENICRIVIROC MESYLATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02312219	PET/CT Imaging Companion Study To ACTG A5314		35	2019-02-06	HIV, Inflammation, Atherosclerosis	METHOTREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04334915	Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV	Phase 2	0		HIV Infections	CENICRIVIROC MESYLATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04939311	Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial	Phase 1/2	0		Inflammation, HIV Infection, Cardiovascular Disease	VB-201	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CVC Arm (Arm A) vs Placebo for CVC Arm (Arm B): deaths from any cause	0 of 74	0 of 36	110	NCT05630885	Trial comparisons
CVC Arm (Arm A) vs Placebo for CVC Arm (Arm B): serious adverse events	4 of 74	2 of 36	110	NCT05630885	Trial comparisons
Low Dose Methotrexate vs Placebo: serious adverse events	0 of 12	0 of 16	28	NCT02312219	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043494

GET https://conductscience.org/api/diseases/v1/MONDO_0043494/drugs

API reference For AI assistants